Cyclodextrin‐soluble angiotensin‐converting enzyme 2 (CD‐sACE2) inclusion compounds can be useful in the treatment of SARS‐CoV‐2 infections by blocking S‐proteins . On the basis of the current research evidence, the authors believe that CD‐sACE2 inclusion compounds have the potential to treat COVID‐19.
Angiotensin‐converting enzyme 2 (ACE2) is a metalloproteinase, a type I transmembrane glycoprotein consisting of an extracellular catalytic domain with an N‐terminal, a small transmembrane fragment and a short C‐terminal intracellular tail. The extracellular region of ACE2 can be cleaved by metalloproteinases, resulting in the release from the cell surface of an extracellular region with enzymatic activity. This extracellular region is soluble ACE2 (sACE2).
ACE2 has been identified as the main receptors for SARS‐CoV and SARS‐CoV‐2.
The formation of a complex of CD and sACE2 can effectively improve the water solubility of sACE2 so it meets the requirements for drug atomization inhalation. The inclusion conjugates release sACE2 after entering the body via atomization or other drug delivery means, and the released sACE2 combines with SARS‐CoV‐2 S‐proteins to block the virus’s ability to infect and destroy human cells.
All the ACE2‐receptor viruses can be blocked by sACE2. So no matter how SARS‐CoV‐2 is mutated, as long as it infects humans by binding the S‐proteins to receptors, the complex can work. The CD-solubilized sACE2 can be administered by inhalation, iv injection, eye drops, etc.
Pengfei Sun, Xiaosheng Lu, Chao Xu, Yanjin Wang, Wenjuan Sun, Jianing Xi (2020) CD‐sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID‐19). Journal of medical Virology https://doi.org/10.1002/jmv.25804